Long-term Treatment with Propagermanium Suppresses Atherosclerosis in WHHL Rabbits
Authors:
- Hiroaki ShimokawaHSHiroaki Shimokawa
- Eriko TanakaETEriko Tanaka
- Kunio MorishigeKMKunio Morishige
- Masahiro FuchigamiMFMasahiro Fuchigami
- Yoshiro IshiwataYIYoshiro Ishiwata
- Kouji MatsushimaKMKouji Matsushima
- Akira TakeshitaATAkira Takeshita
- 1 February 2003
- journal article
- research article
- Published by Wolters Kluwer Health in Journal of Cardiovascular Pharmacology
- Vol. 41 (2) , 171-177
Abstract
Macrophages play an important role in the pathogenesis of atherosclerosis, for which monocyte chemoattractant protein (MCP)-1 and CCR2 chemokine receptors may be involved. The authors have recently demonstrated that propagermanium exerts inhibitory effect on the CCR2 receptors. In the current study, the authors examined whether the organic germanium suppresses the MCP-1–induced monocyte migration in vitro and the development of atherosclerosis in WHHL rabbits in vivo. In the in vitro experiment, propagermanium concentration-dependently suppressed the MCP-1–induced migration of THP-1 cells. In the in vivo experiment, 20 WHHL rabbits were randomly divided into two groups; one group was treated with oral administration with propagermanium (9 mg/kg/day) for 3 months, and another group served as a control (n = 10 each). After 3 months, the aorta was isolated and stained with oil red O staining, and neointimal formation was quantified. Macrophage accumulation in the aorta was also evaluated by immunostaining. Long-term treatment with propagermanium did not affect the serum lipid profiles. However, the treatment significantly suppressed the oil red O–positive area of the total aorta (p < 0.05). Similarly, propagermanium significantly suppressed the intimal lesions (maximal intimal thickness and intimal area) and macrophage staining–positive area (all p < 0.05). A significant positive correlation was noted between macrophage staining–positive area and intimal lesions (p < 0.0001). These results indicate that long-term treatment with propagermanium suppresses the development of atherosclerosis in WHHL rabbits, suggesting its usefulness for the treatment of atherosclerotic vascular disease in humans.Keywords
This publication has 17 references indexed in Scilit:
- An Anti-Inflammatory Drug, Propagermanium, May Target GPI-Anchored Proteins Associated with an MCP-1 Receptor, CCR2Journal of Interferon & Cytokine Research, 2001
- Rho-Kinase Is Involved in Macrophage-Mediated Formation of Coronary Vascular Lesions in Pigs In VivoArteriosclerosis, Thrombosis, and Vascular Biology, 2000
- MCP-1 deficiency reduces susceptibility to atherosclerosis in mice that overexpress human apolipoprotein BJournal of Clinical Investigation, 1999
- Absence of CC chemokine receptor-2 reduces atherosclerosis in apolipoprotein E-deficient miceAtherosclerosis, 1999
- Chemokine Receptor CCR2 Expression and Monocyte Chemoattractant Protein-1–Mediated Chemotaxis in Human MonocytesArteriosclerosis, Thrombosis, and Vascular Biology, 1998
- Hepatoprotective Effect of Propagermanium on Corynebacterium parvum and Lipopolysaccharide‐Induced Liver Injury in MiceScandinavian Journal of Immunology, 1998
- Decreased lesion formation in CCR2−/− mice reveals a role for chemokines in the initiation of atherosclerosisNature, 1998
- The pathogenesis of atherosclerosis: a perspective for the 1990sNature, 1993
- Monocyte chemoattractant protein-1 in human atheromatous plaques.Journal of Clinical Investigation, 1991
- Expression of monocyte chemoattractant protein 1 in macrophage-rich areas of human and rabbit atherosclerotic lesions.Proceedings of the National Academy of Sciences, 1991